Please wait a minute...
European Journal of Gynaecological Oncology  2017, Vol. 38 Issue (2): 209-213    DOI: 10.12892/ejgo3446.2017
Original Research Previous articles | Next articles
Application of combined intraperitoneal and intravenous neoadjuvant chemotherapy in senile patients with advanced ovarian cancer and massive ascites
E.L. Liu1, *(), R.R. Mi2, D.H. Wang2, L.Q. Wang1, Y.M. Zhang1, W.M. Chen1
1 Department of Obstetrics and Gynecology, Tangshan Worker Hospital, Hebei Medical University, Tangshan, China
2 Department of Obstetrics and Gynecology, Tianjin General Hospital, Tianjin Medical University, Tianjin, China
Download:  PDF
Export:  BibTeX | EndNote (RIS)      
Abstract  
Objective: The aim of this study was to explore the effects of neoadjuvant chemotherapy in senile patients with advanced ovarian cancer and ascites. Materials and Methods: One hundred eight senile patients with advanced ovarian cancer and ascites were randomly divided into two groups: experimental and control groups. Patients in the experimental group were treated with two courses of intraperitoneal combined with intravenous neoadjuvant chemotherapy, followed by cytoreductive surgery, and six courses of intravenous chemotherapy, while the patients in the control group only received cytoreductive surgery and six to eight courses of intravenous chemotherapy. Results: The operation duration, blood loss, ideal success rate of cytoreductive surgery, and prognosis of the two groups were then compared. Thirty-eight patients in the experimental group successfully received cytoreductive surgery, accounting for 74.14%, while only 23 patients in the control group received cytoreductive surgery successfully, accounting for 46%, showing significant difference between the two groups (p = 0.0054). The mean blood loss and operation duration in the experimental group were significantly less than those in the control group (p < 0.001). However, the median survival and the median progression-free survival showed no statistical difference between the two groups (p > 0.05). Conclusions: Neoadjuvant chemotherapy can obviously shorten the operation duration, reduce the intraoperative blood loss, and improve the ideal success rate of cytoreductive surgery, but does not obviously improve the prognosis.
Key words:  Abdominal combined with venous neoadjuvant chemotherapy      Senile patients      Advanced ovarian cancer      Ascites     
Published:  10 April 2017     
*Corresponding Author(s):  E.L. LIU     E-mail:  enlingliu@126.com

Cite this article: 

E.L. Liu, R.R. Mi, D.H. Wang, L.Q. Wang, Y.M. Zhang, W.M. Chen. Application of combined intraperitoneal and intravenous neoadjuvant chemotherapy in senile patients with advanced ovarian cancer and massive ascites. European Journal of Gynaecological Oncology, 2017, 38(2): 209-213.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo3446.2017     OR     https://ejgo.imrpress.com/EN/Y2017/V38/I2/209

[1] K. Takeuchi, M. Sawada, A. Takeda, A. Yoshida, M. Sugimoto, M. Fujita, H. Morita. Juvenile granulosa cell tumor with massive ascites: A case report and immunohistochemical study of ascites formation[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 281-283.
[2] S.G. Kim, Y.S. Kim, H.J. Lee. A giant fibroma associated with Meigs' syndrome misdiagnosed as a giant myoma: a case report[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 134-137.
[3] Ji Young Kim, Kyung-Min Park, Yosep Chong, Eun Jung Lee, Young Lee, Chan Joo Kim, Yong Seok Lee. Ovarian hemangioma mimicking ovarian malignancy: a rare case report[J]. European Journal of Gynaecological Oncology, 2019, 40(3): 484-486.
[4] W.Y. Chay, A. Kumar, P.J. Hoskins, A.V. Tinker. Single-agent bevacizumab for the management of refractory malignant effusions in heavily pretreated patients with recurrent high-grade serous cancers of the ovary, fallopian tube or peritoneum: results from a single institution[J]. European Journal of Gynaecological Oncology, 2018, 39(6): 877-880.
[5] Y. Shimizu, T. Nakanishi, K. Sasamoto, S. Kondo. Use of 7.5 mg/kg of bevacizumab to palliate symptomatic malignant ascites in recurrent ovarian cancer[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 404-407.
[6] Yong-Soon Kwon, Jae Young Kwack, Kyong Shil Im, Eunhye Park. Chylous ascites after lymphadenectomy for gynecologic malignancies: the conservative treatment[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 253-256.
[7] D. Vázquez-Vicente, B. Navarro, J.E. García, B. Fernández, J. Urbano, J. Plaza. Management of a postsurgical chylous ascites following a laparoscopic retroperitoneal para-aortic lymphadenectomy[J]. European Journal of Gynaecological Oncology, 2018, 39(1): 151-153.
[8] C. Sofoudis, S. Balamoti, X. Grammatoglou, D. Gkolias, E. Papamargaritis, A. Gerolymatos. Enormous cellular ovarian fibroma with minor sex cord elements mimicking ovarian cancer: a rare case[J]. European Journal of Gynaecological Oncology, 2017, 38(6): 968-970.
[9] G. Ji, F. Lv, P. Yang. Gross painless transudative ascites in a patient with ovarian cancer[J]. European Journal of Gynaecological Oncology, 2017, 38(3): 453-455.
[10] P.E. Heudel, M. Devouassoux-Shisheboran, S. Taieb, C. Genestie, F. Selle, P. Morice, R. Rouzier, I. Ray-Coquard. Multidisciplinary management of advanced ovarian cancer for an optimal therapeutic strategy[J]. European Journal of Gynaecological Oncology, 2017, 38(2): 175-180.
[11] S.J. Liu, W. Lv, M. Shi. Sclerosing stromal tumor of the ovary in a perimenopausal woman: a case report[J]. European Journal of Gynaecological Oncology, 2017, 38(2): 326-328.
[12] C. Sofoudis, P. Kouiroukidou, K. Louis, K. Karasaridou, K. Toutounas, A. Gerolymatos, E. Papamargaritis. Enormous ovarian fibroma with elevated Ca-125 associated with Meigs' syndrome. Presentation of a rare case[J]. European Journal of Gynaecological Oncology, 2016, 37(1): 142-143.
No Suggested Reading articles found!